Com-COV Investigations into vaccine administration comparisons
REACT-2 Studies of sero-prevalence of antibodies in the UK
Biobank - database and health evaluations in UK
Sarscov2 Immunity & REinfection EvaluatioN): The impact of detectable anti SARS-COV2 antibody on the incidence of COVID-19 in healthcare workers
Platform randomised trial of treatments in the Community for Epidemic and Pandemic Diseases. PRINCIPLE is currently evaluating usual care alone versus usual care plus favipiravir, and usual care alone versus Ivermectin, and usual care. Favipiravir is an antiviral used to treat influenza. Ivermectin is antiparasitic used to treat a variety of infections.
Analysis of the Steroids in COVID-19 (STOIC) trial, a phase 2 trial designed to evaluate the efficacy of the widely used inhaled glucocorticoid budesonide in individuals
OCTAVE Study in Immunosuppressed Populations
The initial data shows that 40% of people in the patient groups studied mounted a low serological immune response after two SARS-CoV-2 vaccines.
The data also shows that approximately 11% of immunocompromised patients fail to generate any antibodies 4 weeks after two vaccines.
The proportion of patients with lower levels of antibody reactivity was dependant on the disease cohort, with 87% of those with Rituximab treated ANCA-Associated Vasculitis, 51% of those with inflammatory arthritis, 29% of those on Haemodialysis, 42% of those on Haemodialysis receiving immunosuppressive therapy, 36% of those with Hepatic disease, 10% of those with solid cancer, 33% of those with Haematological malignancies, and 17% of patients who have undergone haemopoietic stem cell transplant responding less well than the baseline for healthy subjects.